Regorafenib and pembrolizumab in pre-treated hepatocellular carcinoma

Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the Phase II study (NCT04696055) of regorafenib plus pembrolizumab in patients with hepatocellular carcinoma (HCC), who had previously received at least one checkpoint inhibitor, mostly atezolizumab plus bevacizumab, in the first line. Another cohort of patients had undergone several other treatment regimens. The overall survival (OS) across all patients was quite low, with the OS rates for regorafenib plus pembrolizumab being similar to those typically treated with regorafenib alone followed by sorafenib. Neither treatment group met the primary endpoint of the study. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.